Novartis news - the latest biotech news from Labiotech.eu

Seven pharma companies form alliance to prepare for future pandemics

Jim Cornall — Thu, 20 Jul 2023 14:00:00 +0000

Seven pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics. The seven companies are AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda. The INTREPID alliance creation is in support of the 100 Days Mission, which seeks to have […]

The post Seven pharma companies form alliance to prepare for future pandemics appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Boost for Charcot-Marie-Tooth patients as Novartis acquires DTx Pharma

Jim Cornall — Tue, 18 Jul 2023 09:00:00 +0000

DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its fatty acid ligand conjugated oligonucleotide (FALCON) platform, has been acquired by Novartis. The FALCON platform enables the delivery and activity of small interfering RNA (siRNA) therapeutics to tissues beyond the liver, enhancing biodistribution and cellular uptake. DTx Pharma’s lead […]

The post Boost for Charcot-Marie-Tooth patients as Novartis acquires DTx Pharma appeared first on Labiotech.eu.

Novartis acquires Chinook Therapeutics for $3.2B

Jim Cornall — Fri, 16 Jun 2023 09:30:00 +0000

Novartis has entered into an agreement to acquire Chinook Therapeutics, a Seattle, Washington, based clinical stage biopharmaceutical company with two high-value, late-stage medicines in development for rare, severe chronic kidney diseases. The agreed deal, which is subject to customary closing conditions, is in line with Novartis’ strategy to focus on innovative medicines and will expand […]

The post Novartis acquires Chinook Therapeutics for $3.2B appeared first on Labiotech.eu.

Chronic myeloid leukemia: Novartis survey signals need for better patient-physician communication

Roohi Mariam Peter — Fri, 09 Jun 2023 11:28:34 +0000

Only 19% to 26% of patients with chronic myeloid leukemia (CML) discuss treatment decisions with their physician, a survey by Swiss-based pharmaceutical Novartis has revealed. The Survey of Unmet Needs in CML (CML SUN), which investigated how patients and physicians felt about current treatment options, joint decision-making, and treatment satisfaction, also found that 39% to […]

The post Chronic myeloid leukemia: Novartis survey signals need for better patient-physician communication appeared first on Labiotech.eu.

Novartis buys AVROBIO cystinosis gene therapy program for $87.5M

Jim Cornall — Fri, 26 May 2023 08:10:00 +0000

AVROBIO, Inc., a clinical-stage gene therapy company working to free people from a lifetime of genetic disease, has agreed to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis for $87.5 million in cash. AVROBIO retains full rights to its portfolio of first-in-class HSC gene therapies for […]

The post Novartis buys AVROBIO cystinosis gene therapy program for $87.5M appeared first on Labiotech.eu.

Pharming immunodeficiency drug given FDA approval

Jim Cornall — Wed, 29 Mar 2023 15:43:17 +0000

Pharming Group N.V. has announced that the US Food and Drug Administration (FDA) has approved Joenja (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. Pharming’s Joenja, an oral, selective PI3Kδ inhibitor, is the first and only treatment approved in the […]

The post Pharming immunodeficiency drug given FDA approval appeared first on Labiotech.eu.

Cell and gene therapies gain momentum in Basel

External Contributor — Tue, 17 Jan 2023 10:52:06 +0000

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the globe, and a growing number are choosing the Swiss city of Basel as their base. These companies are taking advantage of the talent pool, academic institutions and investors that the area has to offer, culturing […]

The post Cell and gene therapies gain momentum in Basel appeared first on Labiotech.eu.

STALICLA signs agreement with Novartis on neurodevelopmental disorders

Jim Cornall — Mon, 09 Jan 2023 10:16:27 +0000

STALICLA SA, a clinical-stage biotech company advancing the first precision neurobiology platform for patients with neurodevelopmental disorders, has entered into an exclusive in-licensing agreement with Novartis to develop mavoglurant as a treatment for substance-use disorder and neurodevelopmental disorders (NDDs). Mavoglurant has previously been tested in more than 1,800 patients and demonstrated a good safety and […]

The post STALICLA signs agreement with Novartis on neurodevelopmental disorders appeared first on Labiotech.eu.

Novartis Biome UK Heart Health Catalyst 2022 winners announced

Jim Cornall — Thu, 06 Oct 2022 08:37:26 +0000

Novartis Pharmaceuticals UK has announced that Xim, creators of Lifelight, and PocDoc are the successful companies of the Novartis Biome UK Heart Health Catalyst 2022, in partnership with Medtronic, RYSE Asset Management, Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+. Lifelight and PocDoc will receive support to scale their innovative digital […]

The post Novartis Biome UK Heart Health Catalyst 2022 winners announced appeared first on Labiotech.eu.

Allarity Therapeutics drug no longer commercially viable or in shareholders’ best interest

Liza Laws — Wed, 03 Aug 2022 13:08:19 +0000

Allarity Therapeutics, after meeting with the US Food and Drug Administration (FDA), has decided a growth factor receptor drug it licensed from Novartis is no longer commercially viable or in the best interests of its shareholders. A type C advisory meeting was held between Allarity and the FDA to discuss a development path for dovitinib. […]

The post Allarity Therapeutics drug no longer commercially viable or in shareholders’ best interest appeared first on Labiotech.eu.

Radiopharmaceuticals gain traction for cancer theranostics potential

Jonathan Smith — Thu, 14 Jul 2022 07:00:00 +0000

After decades of neglect from big pharma, radiopharmaceuticals are generating major oncology deals globally. This could lead to a boom in cancer drugs that can serve as both treatments and diagnostics, or “theranostics.” Over the last few years, there has been big activity from companies developing drugs that use radioactivity to destroy tumors. Just this […]

The post Radiopharmaceuticals gain traction for cancer theranostics potential appeared first on Labiotech.eu.

Novartis Pharmaceuticals UK launches health-tech investor partnership for cardiovascular care

Jim Cornall — Tue, 05 Jul 2022 13:53:05 +0000

Novartis Pharmaceuticals UK has launched the Novartis Biome UK Heart Health Catalyst 2022, in a world-first investor partnership with Medtronic ltd, RYSE Asset Management, and Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+. The initiative aims to identify and implement solutions that empower patients to improve their heart health, and to […]

The post Novartis Pharmaceuticals UK launches health-tech investor partnership for cardiovascular care appeared first on Labiotech.eu.

A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology

Clara Rodríguez Fernández — Mon, 11 Oct 2021 08:00:00 +0000

CAR-T therapy has been hailed as a cure for cancer, but what really is this ‘miraculous technology’ and what can we actually expect from it? The field of immuno-oncology is booming with billions of euros in investment. The ability to rewire our own immune system to fight cancer has certainly created huge expectations. After the […]

The post A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology appeared first on Labiotech.eu.

British Diagnostics Biotech Becomes Social Enterprise After Acquisition

Anita Chakraverty — Fri, 30 Jul 2021 08:36:53 +0000

UK rapid diagnostics company Mologic will convert into a social enterprise after being acquired by a group of philanthropic funds and investors, in what experts predict may become an increasingly popular trend. The British biotech Mologic will entirely reinvest any profits into widening global access to affordable medical technology after being acquired in a deal […]

The post British Diagnostics Biotech Becomes Social Enterprise After Acquisition appeared first on Labiotech.eu.

EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls

Jonathan Smith — Tue, 27 Apr 2021 10:20:40 +0000

While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations centered mostly on improving existing approaches. Which areas of multiple sclerosis treatment need more options? At the end of March, the EMA made key decisions on three treatments for multiple sclerosis (MS), a chronic neurodegenerative disease affecting 2.5 million people […]

The post EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls appeared first on Labiotech.eu.

Update: Novartis’ Gene Therapy Zolgensma Gets Nod from EU

Jonathan Smith — Tue, 19 May 2020 16:15:40 +0000

Update (19/05/2020): The gene therapy Zolgensma, developed by the big pharma Novartis and approved in the US last year, has received conditional approval in Europe for the treatment of spinal muscular atrophy (SMA). The gene therapy is approved to treat patients with a clinical diagnosis of SMA type 1 or SMA patients that have up […]

The post Update: Novartis’ Gene Therapy Zolgensma Gets Nod from EU appeared first on Labiotech.eu.

Update: FDA Imposes No Penalties for Novartis Data Manipulation Scandal

Jonathan Smith — Thu, 02 Apr 2020 10:25:46 +0000

Update (02/04/2020): The FDA has concluded an investigation into a data manipulation scandal surrounding the approval of Novartis’ gene therapy Zolgensma, and has decided against sanctions. The FDA launched an investigation into the manipulated data surrounding the gene therapy application last year, and recently reported that the investigated data violations didn’t meet the threshold for […]

The post Update: FDA Imposes No Penalties for Novartis Data Manipulation Scandal appeared first on Labiotech.eu.

Novartis Enters RNA Therapeutics with Medicines Company Merger

Jonathan Smith — Mon, 25 Nov 2019 18:19:48 +0000

Novartis is to acquire The Medicines Company and its late-stage RNA interference drug designed to protect against cardiovascular disease in twice-yearly shots. Novartis will pay €8.8B ($9.7B) to acquire The Medicines Company, which is based in the US and focuses on developing the RNA drug inclisiran for the treatment of cardiovascular disease and renal impairment. […]

The post Novartis Enters RNA Therapeutics with Medicines Company Merger appeared first on Labiotech.eu.

European Project Launches to Tailor Autoimmune Disease Treatments

Jonathan Smith — Thu, 31 Oct 2019 14:11:19 +0000

Public and private organizations across Europe will pool their resources in an €80M project to discover biomarkers that can predict which patients will respond best to treatments for autoimmune diseases. The project is called Taxonomy, Treatments, Targets and Remission, or 3TR for short, and is funded by the EU’s Innovative Medicines Initiative for the next […]

The post European Project Launches to Tailor Autoimmune Disease Treatments appeared first on Labiotech.eu.

Trial Testing Spinal Application of Zolgensma Put on Hold by FDA

Jonathan Smith — Wed, 30 Oct 2019 16:34:08 +0000

The FDA has placed a partial hold on clinical trials testing a new application method for Zolgensma, Novartis’ gene therapy for the genetic disease spinal muscular atrophy, after it showed the potential to cause serious side effects in animal models. Spinal muscular atrophy is a life-threatening condition that usually arises when the patient is between […]

The post Trial Testing Spinal Application of Zolgensma Put on Hold by FDA appeared first on Labiotech.eu.